Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) Stock Has Consensus Price Target of $52.25 According to Analysts
Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latigo Biotherapeutics Announces CEO Transition to Support the Company's Next Phase of Growth
Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November
Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It
Latigo Biotherapeutics (NASDAQ:LTGO) Hits New 12-Month Low – Here’s Why
Latigo Biotherapeutics, Inc.’s Quiet Period Will End on September 16th (NASDAQ:LTGO)
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public
Latigo Biotherapeutics (NASDAQ:LTGO) Director James Tananbaum Buys 140,000 Shares
Latigo Biotherapeutics (NASDAQ:LTGO) Major Shareholder Foresite Capital Management V, Acquires 140,000 Shares
Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain